IMMUNEONCO BIOPHARMACEUTICALS (SHAN revenue breakdown overview

IMMUNEONCO BIOPHARMACEUTICALS (SHAN revenue for the last year amounted to 78.92 M HKD, the most of which — 77.35 M HKD — came from its highest performing source at the moment, Out-Licensing Fee. The greatest contribution to the revenue figure was made by China — last year it brought IMMUNEONCO BIOPHARMACEUTICALS (SHAN 80.39 M HKD, and the year before that — 426.53 k HKD.